LillyDirect tirzepatide is branded Zepbound sold through Lilly's direct channel; compounded tirzepatide is a patient-specific preparation dispensed by a state-licensed 503A pharmacy. Both require a prescription. They are not the same finished product, and the useful comparison goes beyond price to dose format, formulation, cash terms, pharmacy oversight and follow-up.
For people paying directly for weight management, the clearest difference is standardization. LillyDirect supplies Lilly-manufactured, fixed-strength Zepbound vials. A compounding pharmacy prepares a formulation for an individual prescription, with the concentration, inactive ingredients and beyond-use date stated on that pharmacy's label.
What LillyDirect tirzepatide includes
LillyDirect is Lilly's direct-to-consumer channel, not a separate tirzepatide formulation. Its single-dose vial option contains one weekly dose per vial, and one 28-day prescription contains four vials. A needle and syringe are purchased separately.
As of September 2026, Lilly's current Zepbound page lists every vial strength from 2.5 mg through 15 mg:
| Zepbound vial strength | Starting self-pay price per 28 days | Important condition |
|---|---|---|
| 2.5 mg/0.5 mL | $299 | Starting strength |
| 5 mg/0.5 mL | $399 | Terms apply |
| 7.5 mg/0.5 mL | $449 | Refill within 45 days for program price |
| 10 mg/0.5 mL | $449 | Refill within 45 days for program price |
| 12.5 mg/0.5 mL | $449 | Refill within 45 days for program price |
| 15 mg/0.5 mL | $449 | Refill within 45 days for program price |
Lilly states that regular prices apply if the higher-dose refill falls outside that window: $499 for 7.5 mg and $699 for 10 mg, 12.5 mg or 15 mg. Those are manufacturer terms, not insurance benefits, and they can change. The tirzepatide cost breakdown keeps Promise pricing and other payment routes in one place.
LillyDirect vs compounded tirzepatide at a glance
| Question | LillyDirect Zepbound vial | Compounded tirzepatide |
|---|---|---|
| What is dispensed? | Lilly-manufactured brand product | A pharmacy-prepared formulation for an individual prescription |
| Available strengths | Six fixed vial strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg | Concentration and prescribed amount vary by prescription and pharmacy |
| Prescription | Valid prescription required; self-pay program requires an on-label use | Patient-specific prescription required |
| Payment | Vial route is self-pay only | Commonly self-pay; coverage varies |
| Label to follow | Zepbound prescribing information and package label | The dispensing pharmacy's patient-specific label |
| Product review | Reviewed as a standardized branded product | The individual compounded preparation is not reviewed as a branded finished product |
Zepbound is the approved brand; compounded tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. That distinction does not decide whether either route is clinically appropriate for a particular person.
What 503A status means in September 2026
The shortage-era rules have changed, but patient-specific compounding did not become a blanket yes-or-no category. In an April 2026 clarification, FDA said tirzepatide was not on its drug-shortage list or 503B bulks list. The agency also restated that section 503A pharmacies compound for an identified patient on a prescription and may not regularly, or in inordinate amounts, make products that are essentially copies of a commercially available drug.
A prescriber's documented determination that a compounded preparation creates a significant difference for an individual patient can matter under that framework. The full compounded tirzepatide explainer covers how the prescription and pharmacy roles fit together. Regulatory status is one factor, not a marketing gate or warning; a licensed provider may still prescribe a compounded formulation when clinically justified, and that decision belongs to the patient and prescriber.
The medication decision comes before the channel
A LillyDirect-versus-compounding comparison only makes sense after a clinician decides tirzepatide is the appropriate molecule. Semaglutide is a different GLP-1 medication that a provider may consider when the clinical profile points elsewhere; choosing it changes the medication and prescription, not merely the fulfillment channel. It should not be exchanged milligram for milligram with tirzepatide. The broader tirzepatide versus semaglutide comparison addresses that separate decision.
The same molecule is not the same finished product
The clinical rationale for either tirzepatide route draws on research into the molecule, but product-level evidence is not interchangeable. The early phase 1 program described tirzepatide as a once-weekly peptide with activity at both GIP and GLP-1 receptors (Coskun et al., Molecular Metabolism 2018).
In SURMOUNT-1, 2,539 adults with obesity or overweight without diabetes were randomized to manufactured tirzepatide or placebo. At 72 weeks, the trial reported mean weight changes of -15.0%, -19.5% and -20.9% with 5 mg, 10 mg and 15 mg, respectively, versus -3.1% with placebo (Jastreboff et al., NEJM 2022). Those results describe tirzepatide as studied under trial controls. They do not test the concentration, sterility, stability or inactive ingredients of an individual compounded vial.
Questions that make the comparison concrete
A useful offer comparison should answer the same questions on both sides:
- What exact product and concentration will appear on the dispensing label?
- Is the quoted amount for 28 days, and are clinical review, supplies, delivery and follow-up included or separate?
- Does a refill deadline change the cash price?
- Which pharmacy dispenses the medication, and who answers medication questions after delivery?
- What beyond-use or expiration date controls, and what storage instructions appear on the actual label?
- If changing routes, has the prescriber issued a new prescription that accounts for the new concentration and device?
At Promise, a licensed provider reviews every request and not everyone qualifies. The prescribed amount and the pharmacy label control; a price table or another patient's vial does not.
The practical difference
LillyDirect offers a standardized brand vial with published manufacturer cash terms. Patient-specific compounding is a separate route in which the prescriber and 503A pharmacy define the preparation for the individual prescription. Neither description makes one route automatically right for everyone, and switching between them is not a simple supplier swap. The relevant choice is the product a provider can justify, the pharmacy can accurately dispense and the patient can use with accountable follow-up.